In Brief: Glaxo Wellcome/British Biotech
Executive Summary
Glaxo Wellcome/British Biotech: Glaxo pulls out of development of British Biotech's oral formulation of lexipafant, a synthetic platelet-activating factor receptor antagonist/anti-inflammatory for asthma, after funding testing of the drug since 1992. British Biotech maintains full commercial rights to product and will continue to develop it for treatment of pancreatitis...